Palmar Hyperhidrosis Market

Market Overview:

The 7 major palmar hyperhidrosis markets reached a value of US$ 231.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 352.6 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.

The palmar hyperhidrosis market has been comprehensively analyzed in IMARC's new report titled "Palmar Hyperhidrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Palmar hyperhidrosis refers to a condition characterized by excessive and uncontrollable sweating of the palms. Individuals suffering from this ailment often experience damp or dripping hands, regardless of temperature or physical activity. The primary symptom is the presence of abnormally high sweat production in the palms, which can lead to discomfort, difficulty in performing tasks requiring fine motor skills, and social anxiety due to the embarrassment of constantly sweaty hands. This condition can significantly impact a patient's quality of life, affecting daily activities, such as shaking hands, holding objects, using touchscreens, etc. The diagnosis of palmar hyperhidrosis involves a thorough medical history assessment, physical examination, and evaluation of the pattern and severity of sweating. Physicians might perform a starch-iodine test wherein an iodine solution is sprayed on the palm and, after drying, sprinkled with starch to obtain a visual representation of the sweat pattern and determine the extent of the condition.

The escalating incidences of genetic predisposition and overactivity of the sweat glands, particularly those located in the hands, are primarily driving the palmar hyperhidrosis market. In addition to this, the inflating utilization of effective treatments, such as antiperspirants containing aluminum chloride, iontophoresis, and botulinum toxin injections, to aid patients in managing their symptoms and enhancing the quality of life, is also creating a positive outlook for the market. Moreover, the widespread adoption of minimally invasive surgical procedures, including endoscopic thoracic sympathectomy (ETS), where nerve pathways that trigger excessive sweating are interrupted, is further augmenting the market growth. Apart from this, the increasing usage of cognitive-behavioral therapies and biofeedback techniques, as they aid in addressing the emotional and mental aspects associated with palmar hyperhidrosis, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advancing technology in laser treatments and microwave thermolysis that focus on sweat gland ablation, leading to controlled sweating in individuals suffering from the illness, is also augmenting the market growth. Furthermore, the escalating demand for innovative equipment like focused ultrasound, which offers a non-invasive way to treat medical devices tailored to manage the disease, is expected to drive the palmar hyperhidrosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the palmar hyperhidrosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for palmar hyperhidrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the palmar hyperhidrosis market in any manner.

Key Highlights:

• Palmar hyperhidrosis affects roughly 3% of the population in the United States.
• It's most common in adults between the ages of 20 to 60.
• Most persons with palmar hyperhidrosis develop symptoms before the age of twelve.
• Palmar hyperhidrosis symptoms frequently do not improve with age, with 88% of persons reporting that their symptoms either remain the same or worsen over time.
• Palmar hyperhidrosis affects all ethnicities; however, the Japanese are more affected than other ethnic groups.

Drugs:

Dexmecamylamine is the S-enantiomer of mecamylamine, which selectively inhibits the acetylcholine nicotinic receptor. Dexmecamylamine is supposed to suppress the sympathetic ganglion, which reduces parasympathetic side effects. It is now in Phase II development for the treatment of palmar hyperhidrosis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the palmar hyperhidrosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the palmar hyperhidrosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current palmar hyperhidrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the palmar hyperhidrosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the palmar hyperhidrosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the palmar hyperhidrosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of palmar hyperhidrosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of palmar hyperhidrosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of palmar hyperhidrosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with palmar hyperhidrosis across the seven major markets?
• What is the size of the palmar hyperhidrosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of palmar hyperhidrosis?
• What will be the growth rate of patients across the seven major markets?
   

Palmar Hyperhidrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for palmar hyperhidrosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the palmar hyperhidrosis market?
• What are the key regulatory events related to the palmar hyperhidrosis market?
• What is the structure of clinical trial landscape by status related to the palmar hyperhidrosis market?
• What is the structure of clinical trial landscape by phase related to the palmar hyperhidrosis market?
• What is the structure of clinical trial landscape by route of administration related to the palmar hyperhidrosis market?